We read with interest the letter from May et al. recently published in Critical Care [1] . The authors suggest that overdosing of β-lactams in 108 critically ill patients receiving renal replacement therapy may not be associated with neurotoxicity. We agree that adequate plasmatic levels of β-lactams in critically ill patients with sepsis should be a primary goal and that under-dosing may put the patient at a dangerous risk of treatment failure [2] . We are, however, concerned about the conclusions of this letter and would like to comment on two points.
First, not all β-lactams are equal regarding neurotoxicity, and some may expose the patient to higher risk. A number of studies have reported neurotoxicity of imipenem, especially in patients with brain injury [3, 4] . More recently, several authors have reported neurotoxicity with cefepime. Fugate et al. reported that 7 % to 15 % of critically ill patients treated with cefepime developed definitive or possible neurotoxicity [5] . Hence, renal insufficiency was a major risk factor. We have also observed over the last 2 years similar findings with four cases of cefepime-related neurotoxicity in our intensive care unit (ICU) in patients with chronic renal insufficiency or acute kidney injury.
Second, May et al. defined neurotoxicity as an association of overdose and convulsions. There is, however, strong evidence showing that neurotoxicity of β-lactams can present without seizures [6] . Cefepime-related neurotoxicity has been reported to present mostly as myoclonus and impaired consciousness, confusion, hallucinations, or agitation. Convulsions might be only the most extreme manifestation of the induced encephalopathy toxicity. In our cases, the neurological manifestations were loss of contact, agitation, disorientation and, for two of them, myoclonic twitches and jerks. The observed cefepime trough level of those patients during these events ranged from 144 mg/l to 455 mg/l for an upper therapeutic trough level of 90 mg/l according to our laboratory, while daily doses were 4 to 6 g/day. An electroencephalogram was carried out for each patient and has objectified a toxic encephalopathy pattern or aspecific slow waves with no sign of lobe epilepsy. Every patient experienced a regression of the symptoms with the withdrawal of the offending drug.
To conclude, while we agree that high serum levels of β-lactams should be obtained at the initiation of antibiotic therapy in patients with sepsis, intensivists should not overlook the potential neurotoxicity of some β-lactams with a low therapeutic index such as imipenem and cefepime. The risk of cefepime neurotoxicity should not be underappreciated in patients with neurological symptoms, especially if renal function is impaired.
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We thank Dr Chaïbi et al. for their valuable and insightful comments on our report of the low evidence for an association between supra-therapeutic serum levels of β-lactams (BL) and clinical toxicity in ICU patients with acute renal failure (ARF) treated with intermittent hemodialysis [1] .
Chaïbi et al. point out that neurotoxicity is common among BL, especially in at-risk patients such as those with ARF, and that some BL with a low therapeutic index may induce more neurological events. Several reports described an increased risk for penicillins, imipenem, and fourth generation cephalosporins, and suggested that neurological complications may range from confusion, depressed level of consciousness, and nonspecific encephalopathy to myoclonus, non-convulsive status epilepticus (NCSE), and seizures [6] .
We would like to draw attention to the fact that the majority of those articles were non-human experimental studies, case series, and retrospective reviews, with assessment offering low levels of evidence [7] . To establish a cause-effect relationship between a BL administration and clinical signs of encephalopathy remains a major difficulty because both clinical and electrical signs are non-specific. All the neurological symptoms of clinical encephalopathy may be observed in conditions such as metabolic abnormality, uremic disorder, ICU delirium, withdrawal syndrome, or septic encephalopathy, which are very frequent in ICU septic patients [8] .
In our population, while we may have missed nonconvulsive signs and NCSE, we could not find an association between convulsions and BL observed at the supra-therapeutic level.
Therefore, despite the comments of Chaïbi et al., we consider that the BL neurotoxic threshold is not yet well identified and is still challenging. A proper diagnosis of BL neurological toxicity may be obscured by the overall clinical picture and may easily be attributed to the infectious process or to an underlying metabolic. We estimate that prospective observational studies, including pre-established and precise definitions and design, are still needed to assess BL encephalopathy and the neurotoxic threshold and to conclude on their clinical impact.
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